Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an “exceptionally good” first quarter 2000, the company said last week.U.S. sales grew by 49% to 231 million euros, accounting for 22%
Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an exceptionally good first quarter 2000, the company said last week.
U.S. sales grew by 49% to 231 million euros, accounting for 22% of Scherings total sales, which were reported up 25% to 1.044 billion euros. Net profit was up 22% to 106 million euros ($97.5 million) in the period from January to March.
The companys diagnostics division, which is one of the worlds largest makers of contrast agents, showed a sales increase of 27% to 295 million euros. Schering also makes a best-selling multiple sclerosis drug, Betaferon, and is a leading manufacturer of contraceptives and fertility drugs.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.